ArriVent BioPharma, Inc. (AVBP) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 17, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 12, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the AVBP SEC filings page.
This page shows ArriVent BioPharma, Inc. (AVBP) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 3 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
AVBP remains a development-stage business: rising research costs and operating losses are funded mainly through equity-linked external capital.
FY2025’s net loss of$166.3M was close to operating cash flow of-$160.6M , so reported losses are translating into cash consumption rather than being mainly accounting charges. That alignment coincided with R&D reaching$153.4M and financing cash flow of$203.1M : the business is using outside funding to sustain development spending, not funding it from internally generated cash.
R&D reached
The financing pattern is the clearest balance-sheet signal: FY2025 financing cash flow of
Financial Health Signals
ArriVent BioPharma, Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
ArriVent BioPharma, Inc. passes 1 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
ArriVent BioPharma, Inc. reported a net loss of $166.3M while operations used $160.6M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
ArriVent BioPharma, Inc.'s EBITDA was -$53.2M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. Against the prior quarter it is down 14.0%.
ArriVent BioPharma, Inc. reported -$49.9M in net income in Q2 2026. This represents a decrease of 58.9% from the same quarter a year earlier. Against the prior quarter it is down 15.2%.
ArriVent BioPharma, Inc. earned -$1.05 per diluted share (EPS) in Q2 2026. This represents a decrease of 16.7% from the same quarter a year earlier. Against the prior quarter it is down 9.4%.
Not reported for Q2 2026.
Cash & Balance Sheet
ArriVent BioPharma, Inc. held $154.7M in cash as of Q2 2026; long-term debt is not reported for that period.
Not reported for Q2 2026.
Not reported for Q2 2026.
Margins & Returns
ArriVent BioPharma, Inc.'s ROE was -13.6% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is down 1.0 percentage points from the same quarter a year earlier. Against the prior quarter it is down 0.2 percentage points.
Not reported for Q2 2026.
Not reported for Q2 2026.
Not reported for Q2 2026.
Capital Allocation
ArriVent BioPharma, Inc. invested $42.3M in research and development in Q2 2026. This represents an increase of 52.7% from the same quarter a year earlier. Against the prior quarter it is up 12.6%.
Not reported for Q2 2026.
Not reported for Q2 2026.
AVBP Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| R&D Expenses | $42.3M+52.7% | $37.6M-38.6% | N/A | $32.2M+60.1% | $27.7M+27.3% | $61.3M+261.1% | N/A | $20.1M+40.7% |
| SG&A Expenses | $10.4M+75.4% | $8.5M+54.9% | N/A | $6.1M+48.4% | $5.9M+50.6% | $5.5M+48.2% | N/A | $4.1M+70.1% |
| Operating Income | -$52.7M-56.7% | -$46.1M+30.9% | N/A | -$38.3M-58.1% | -$33.6M-30.8% | -$66.8M-223.0% | N/A | -$24.2M-45.0% |
| EBITDA | -$53.2M | -$46.7M | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$49.9M-58.9% | -$43.3M+32.7% | N/A | -$35.0M-70.1% | -$31.4M-43.5% | -$64.4M-269.7% | N/A | -$20.6M-42.8% |
| EPS (Basic) | -$1.05-16.7% | -$0.96+49.5% | -$0.78-27.9% | -$0.83-36.1% | -$0.90-38.5% | -$1.90-171.4% | -$0.61+92.1% | -$0.61+88.9% |
| EPS (Diluted) | -$1.05-16.7% | -$0.96+49.5% | -$0.78-27.9% | -$0.83-36.1% | -$0.90-38.5% | -$1.90-171.4% | -$0.61 | -$0.61 |
| Diluted Shares (Avg) | 48M+36.0% | 45M+32.9% | N/A | 42M+24.8% | 35M+4.5% | 34M+35.3% | N/A | 34M |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Interest Expense, Income Tax.
AVBP Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $394.7M+46.5% | $349.3M+62.1% | $333.2M+21.2% | $326.6M+11.6% | $269.5M-12.7% | $215.5M-34.3% | $274.9M+68.6% | $292.7M |
| Current Assets | $394.2M+57.6% | $348.7M+87.7% | $332.9M+46.7% | $321.2M+9.9% | $250.1M-18.9% | $185.8M-43.3% | $227.0M+41.9% | $292.4M |
| Cash & Equivalents | $154.7M+37.2% | $62.1M+24.5% | $45.5M-38.7% | $112.7M-60.2% | $112.8M-62.2% | $49.9M-84.3% | $74.3M-50.6% | $282.9M+100.1% |
| Short-Term Investments | $218.4M+77.7% | $264.3M+109.4% | $267.3M+84.9% | $187.6M | $122.9M | $126.2M | $144.6M | $0 |
| Long-Term Investments | $0-100.0% | $0-100.0% | $0-100.0% | $5.1M | $18.8M | $29.4M | $47.7M | $0 |
| Total Liabilities | $27.9M+42.0% | $25.3M+95.4% | $25.9M+50.1% | $21.6M+41.7% | $19.6M+61.0% | $13.0M+28.1% | $17.3M-94.5% | $15.2M |
| Current Liabilities | $27.8M+41.8% | $25.0M+93.0% | $25.9M+50.2% | $21.6M+42.2% | $19.6M+62.3% | $13.0M+29.8% | $17.3M+48.6% | $15.2M |
| Non-Current Liabilities | $33K | $320K | $0-100.0% | $0-100.0% | $0-100.0% | $0-100.0% | $14K-100.0% | $56K |
| Total Equity | $366.8M+46.8% | $324.0M+60.0% | $307.2M+19.2% | $305.0M+9.9% | $249.9M-15.8% | $202.5M-36.3% | $257.7M+268.2% | $277.5M+309.3% |
| Retained Earnings | -$497.9M-49.0% | -$448.0M-48.0% | -$404.6M-69.8% | -$369.1M-69.5% | -$334.1M-69.5% | -$302.7M-72.7% | -$238.3M-51.0% | -$217.7M |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
AVBP Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$39.6M-51.5% | -$41.9M+38.4% | -$30.7M-89.8% | -$35.8M-119.0% | -$26.1M-36.9% | -$68.0M-265.1% | -$16.2M-8.3% | -$16.3M-5.8% |
| Depreciation & Amortization | -$515K | -$559K | N/A | N/A | N/A | N/A | N/A | N/A |
| Stock-Based Compensation | $6.7M+101.3% | $5.5M+141.5% | N/A | $3.7M+329.6% | $3.3M+332.2% | $2.3M+263.4% | N/A | $865K-99.6% |
| Investing Cash Flow | $46.1M+231.2% | $3.6M-90.3% | -$71.2M | -$50.8M | $13.9M | $36.8M | N/A | N/A |
| Financing Cash Flow | $86.1M+14.6% | $54.9M+711.9% | $34.7M+63036.4% | $86.5M+16183.4% | $75.1M+20592.6% | $6.8M-96.4% | $55K+105.2% | $531K+151.4% |
Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Dividends Paid, Share Buybacks.
AVBP Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Return on Equity | -13.6%-1.0pp | -13.4%+18.4pp | N/A | -11.5%-4.1pp | -12.6%-5.2pp | -31.8%-26.3pp | N/A | -7.4% |
| Return on Assets | -12.6%-1.0pp | -12.4%+17.5pp | N/A | -10.7%-3.7pp | -11.7%-4.6pp | -29.9%-24.6pp | N/A | -7.0% |
| Current Ratio | 14.16+1.4x | 13.95-0.4x | 12.83-0.3x | 14.90-4.4x | 12.74-12.8x | 14.34-18.5x | 13.14-0.6x | 19.28 |
| Debt-to-Equity | 0.080.0x | 0.080.0x | 0.080.0x | 0.070.0x | 0.080.0x | 0.060.0x | 0.07 | 0.05 |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Asset Turnover, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| ArriVent BioPharma, Inc. AVBP | FY2025 | N/A | -$166.3M | N/A | $821.5M | — |
| Day One Biopharmaceuticals, Inc. DAWN | FY2025 | $158.2M | N/A | N/A | $2.2B | 51/100 |
| Kura Oncology, Inc. KURA | FY2025 | $67.5M | -$278.7M | N/A | $807.8M | 73/100 |
| Tango Therapeutics, Inc. TNGX | FY2025 | $62.4M | -$101.6M | N/A | $3.7B | 65/100 |
| Immunome, Inc. IMNM | FY2025 | $6.9M | -$212.4M | N/A | $1.9B | 49/100 |
| Praxis Precision Medicines, Inc. PRAX | FY2025 | $0 | -$303.0M | N/A | $6.7B | — |
Where ArriVent BioPharma, Inc. Ranks
Frequently Asked Questions
Is ArriVent BioPharma, Inc. profitable?
No, ArriVent BioPharma, Inc. (AVBP) reported a net income of -$166.3M in fiscal year 2025.
What is ArriVent BioPharma, Inc.'s EBITDA?
ArriVent BioPharma, Inc. (AVBP) had EBITDA of -$180.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is ArriVent BioPharma, Inc.'s return on equity (ROE)?
ArriVent BioPharma, Inc. (AVBP) has a return on equity of -54.1% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is ArriVent BioPharma, Inc.'s operating cash flow?
ArriVent BioPharma, Inc. (AVBP) recorded an outflow of $160.6M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are ArriVent BioPharma, Inc.'s total assets?
ArriVent BioPharma, Inc. (AVBP) had $333.2M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does ArriVent BioPharma, Inc. spend on research and development?
ArriVent BioPharma, Inc. (AVBP) invested $153.4M in research and development during fiscal year 2025.
What is ArriVent BioPharma, Inc.'s current ratio?
ArriVent BioPharma, Inc. (AVBP) had a current ratio of 12.83 as of fiscal year 2025, which is generally considered healthy.
What is ArriVent BioPharma, Inc.'s debt-to-equity ratio?
ArriVent BioPharma, Inc. (AVBP) had a debt-to-equity ratio of 0.08 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is ArriVent BioPharma, Inc.'s return on assets (ROA)?
ArriVent BioPharma, Inc. (AVBP) had a return on assets of -49.9% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is ArriVent BioPharma, Inc.'s P/E ratio?
ArriVent BioPharma, Inc. (AVBP) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $821.5M as of Oct 17, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is ArriVent BioPharma, Inc.'s price-to-sales ratio?
ArriVent BioPharma, Inc. (AVBP) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $821.5M as of Oct 17, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does ArriVent BioPharma, Inc.'s liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, ArriVent BioPharma, Inc. (AVBP) held $312.8M in cash, cash equivalents and investments, and reported an operating cash outflow of $160.6M over that year. Dividing the one by the other, the reported balance equals about 23 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is ArriVent BioPharma, Inc.'s Piotroski F-Score?
ArriVent BioPharma, Inc. (AVBP) has a Piotroski F-Score of 1 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are ArriVent BioPharma, Inc.'s earnings high quality?
ArriVent BioPharma, Inc. (AVBP) reported a net loss of $166.3M while operations used $160.6M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.